SNCE SCIENCE 37 HLDGS INC

Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial

Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial

Partnership with Leading Biotech Company Enrolls 28% of Study Participants with 22x Greater Enrollment Velocity Compared to Traditional Brick-and-Mortar Clinical Trial Sites

RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- today disclosed the latest enrollment figures resulting from its Metasite™ and Patient Recruitment partnership with a leading biotech company whose asthma drug is currently undergoing a Phase 3 clinical trial.

Leveraging its proprietary Metasite™ and Patient Recruitment solutions, Science 37 contributed 28% of all randomized study participants over a 15-month enrollment window. Science 37 averaged 44 patients enrolled per month, while each of the 55 brick-and-mortar sites supporting the trial enrolled an average of two participants per month. Science 37 delivered an enrollment velocity 22x greater than study sites in the trial and reduced the study’s overall time-to-target enrollment.

“When a study sponsor entrusts us to fully accelerate its clinical research, our role becomes twofold,” said Dr. Lianne Marks, Medical Director and Primary Investigator at Science 37. “The first is to improve upon the traditional patient recruitment model using the built-in outreach, screening, and medical consent advantages of our recruitment solution. The second is to further enhance study conduct through our Metasite by expanding participant access to the 90+ percent patient population that is unreachable in brick-and-mortar research,” she added.

Science 37’s Patient Recruitment is available on a standalone basis to clinical research sponsors and CROs looking to enhance their patient enrollment efforts, or in combination with Science 37’s industry-leading flagship Virtual Site, the Metasite™, as part of an accelerated research offering. For more information, please visit

About Science 37

Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Metasite™ and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration. To learn more, visit , or email .

To view studies that Science 37 is actively recruiting for, please visit .

Media Inquiries



Science 37

 



EN
02/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCIENCE 37 HLDGS INC

 PRESS RELEASE

Science 37 Completes Third FDA Inspection, Validating Quality of its D...

Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial MORRISVILLE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, today announced the successful completion of its third FDA inspection, further affirming the quality and compliance of its Direct-to-Patient Site for clinical research. The inspection concluded with a No Action Indicated (NAI) categorization recommendation by the inspector, with no objectionable conditions noted and no Form 483 issued. The review cen...

 PRESS RELEASE

Science 37 and Catalent Announce Partnership Enabling Universal Access...

Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research MORRISVILLE, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- , the leader in expanding patient access to clinical trials, and ®, a global leader in enabling pharma, biotech, and consumer health partners to optimize product development and supply, announced a strategic partnership redefining how investigational medicinal products (IMPs) are delivered directly to patients’ homes for clinical research. Through this collaboration, Catalent supports Science 37’s Direct-to-Patient Clinical Trial Site model by ...

 PRESS RELEASE

Science 37 Completes Second FDA Inspection as Enrollment Leader in Pha...

Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial MORRISVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for clinical research. The inspection resulted in a No Action Indicated (NAI) categorization, with no objectionable conditions noted and no Form 483 issued. Led by Science 37's internal Quality Assurance & Compliance team, the inspection focused on the company’s role...

 PRESS RELEASE

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-...

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation Seasoned Strategist and Former Chief Commercial Officer Poised to Accelerate Access and Equity in Clinical Research MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company’s Chief Commercial Officer, Van Horn’s appointment follows his pivotal role in driving operational excellence and shaping the company’s strategic direction to better prioritize client ...

 PRESS RELEASE

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease...

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company, . The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost half (17 - 47%) of the U.S. enrollment for the study. Recognizing that t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch